BeOne Medicines Ltd.
For the period ended Jun 30, 2025. Filed Aug 6, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Aug 6, 2025
ONC$424.00+1.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 6. Exhibits
See the Exhibit Index below for a list of the exhibits filed as part of, or incorporated by reference into, this Quarterly Report, which Exhibit Index is incorporated herein by reference.
EXHIBIT INDEX
| Exhibit No. · Exhibit Description · Filed/Furnished Herewith · Incorporated by Reference Herein from Form or Schedule · Filing Date · SEC File / Reg. Number | ||||
|---|---|---|---|---|
| 3.1 | Articles of Association of BeOne Medicines Ltd., effective May 27, 2025. | 8-K12G3(Exhibit 3.1) | 5/27/2025 | 000-56752 |
| 3.2 | Organizational Regulations of BeOne Medicines Ltd., effective May 27, 2025. | 8-K12G3(Exhibit 3.2) | 5/27/2025 | 000-56752 |
| 4.1.1 | Amended and Restated Deposit Agreement, dated May 27, 2025, by and between the Company and Citibank, N.A., and the Form of American Depositary Receipt thereunder. | 8-K12G3(Exhibit 4.1.1) | 5/27/2025 | 000-56752 |
| .2 | Form of American Depositary Receipt under the Amended and Restated Deposit Agreement (included in Exhibit 4.1.1) | 8-K12G3(Exhibit 4.1.2) | 5/27/2025 | 000-56752 |
| .3 | Amended and Restated Restricted ADS Letter Agreement, dated May 27, 2025, by and between the Company and Citibank, N.A. | 8-K12G3(Exhibit 4.1.3) | 5/27/2025 | 000-56752 |
| .4 | Amended and Restated Letter Agreement, dated May 27, 2025, by and between the Company and Citibank, N.A. | 8-K12G3(Exhibit 4.1.4) | 5/27/2025 | 000-56752 |
| .5 | Amended and Restated Supplemental Letter Agreement, dated May 27, 2025, by and between the Company and Citibank, N.A. | 8-K12G3(Exhibit 4.1.5) | 5/27/2025 | 000-56752 |
| 10.1# | Executive Employment Agreement, effective May 27, 2025, by and between BeOne Medicines USA, Inc. and John V. Oyler. | 8-K12G3(Exhibit 10.1) | 5/27/2025 | 000-56752 |
| 10.2# | Executive Employment Agreement, effective May 27, 2025, by and between BeOne Medicines (Beijing) Co., Ltd. and Xiaobin Wu. | 8-K12G3(Exhibit 10.2) | 5/27/2025 | 000-56752 |
| 10.3# | Executive Employment Agreement, effective May 27, 2025, by and between BeOne Medicines USA, Inc. and Aaron Rosenberg. | 8-K12G3(Exhibit 10.3) | 5/27/2025 | 000-56752 |
| 10.4# | Executive Employment Agreement, effective May 27, 2025, by and between BeOne Medicines (Shanghai) Co., Ltd. and Lai Wang. | 8-K12G3(Exhibit 10.4) | 5/27/2025 | 000-56752 |
| 10.5# | Executive Employment Agreement, effective May 27, 2025, by and between BeOne Medicines USA, Inc. and Chan Lee. | 8-K12G3(Exhibit 10.5) | 5/27/2025 | 000-56752 |
| 10.6# | Form of Indemnification Agreement, entered into between the Company and its directors and officers. | 8-K12G3(Exhibit 10.6) | 5/27/2025 | 000-56752 |
| 10.7# | Consulting Agreement, effective May 27, 2025, by and between BeOne Medicines USA, Inc. and Xiaodong Wang. | 8-K12G3(Exhibit 10.7) | 5/27/2025 | 000-56752 |
| Exhibit No. | Exhibit Description | Filed/Furnished Herewith | Incorporated by Reference Herein from Form or Schedule | Filing Date | SEC File / Reg. Number |
|---|---|---|---|---|---|
| 10.8# | Independent Non-Executive Director Compensation Policy, as amended | POS AM No. 1 to Registration Statement on Form S-4(Exhibit 10.10) | 5/27/2025 | 333-281324 | |
| 10.9# | 2011 Option Plan, as amended and form of option agreement thereunder | POS AM No. 1 to Registration Statement on Form S-8(Exhibit 99.1) | 5/27/2025 | 333-279980 | |
| 10.10# | Fourth Amended and Restated 2016 Share Option and Incentive Plan | POS AM No. 1 to Registration Statement on Form S-8(Exhibit 99.2.1) | 5/27/2025 | 333-279980 | |
| 10.11# | Form of Global Performance Share Unit Award Agreement for Employees under the Fourth Amended and Restated 2016 Share Option and Incentive Plan | POS AM No. 1 to Registration Statement on Form S-8(Exhibit 99.2.2) | 5/27/2025 | 333-279980 | |
| 10.12# | Form of Global Restricted Share Unit Award Agreement for Non-Employee Directors under the Fourth Amended and Restated 2016 Share Option and Incentive Plan | POS AM No. 1 to Registration Statement on Form S-8(Exhibit 99.2.3) | 5/27/2025 | 333-279980 | |
| 10.13# | Form of Global Restricted Share Unit Award Agreement for Employees under the Fourth Amended and Restated 2016 Share Option and Incentive Plan | POS AM No. 1 to Registration Statement on Form S-8(Exhibit 99.2.4) | 5/27/2025 | 333-279980 | |
| 10.14# | Form of Global Restricted Share Unit Award Agreement for Consultants under the Fourth Amended and Restated 2016 Share Option and Incentive Plan | POS AM No. 1 to Registration Statement on Form S-8(Exhibit 99.2.5) | 5/27/2025 | 333-279980 | |
| 10.15# | Form of Global Non-Qualified Share Option Agreement for Employees under the Fourth Amended and Restated 2016 Share Option and Incentive Plan | POS AM No. 1 to Registration Statement on Form S-8(Exhibit 99.2.6) | 5/27/2025 | 333-279980 | |
| 10.16# | Form of Global Non-Qualified Share Option Agreement for Non-Employee Directors under the Third Amended and Restated 2016 Share Option and Incentive Plan | 10-Q(Exhibit 10.9) | 8/2/2023 | 001-37686 | |
| 10.17# | Form of Global Non-Qualified Share Option Agreement for Non-Employee Consultants under the Fourth Amended and Restated 2016 Share Option and Incentive Plan | POS AM No. 1 to Registration Statement on Form S-8(Exhibit 99.2.8) | 5/27/2025 | 333-279980 | |
| 10.18# | Fifth Amended and Restated 2018 Employee Share Purchase Plan | X | |||
| 10.19 | Letter Agreement, dated May 9, 2025, Regarding the Collaboration Agreement, dated October 31, 2019, by and between BeiGene Switzerland GmbH and Amgen Inc. | X | |||
| 31.1 | Certification of Principal Executive Officer Required Under Rule 13a‑14(a) and 15d‑14(a) of the Securities Exchange Act of 1934, as amended | X | |||
| Exhibit No. | Exhibit Description | Filed/Furnished Herewith | Incorporated by Reference Herein from Form or Schedule | Filing Date | SEC File / Reg. Number |
| 31.2 | Certification of Principal Financial Officer Required Under Rule 13a‑14(a) and 15d‑14(a) of the Securities Exchange Act of 1934, as amended | X | |||
| 32.1* | Certification of Principal Executive Officer and Principal Financial Officer Required Under Rule 13a‑14(b) of the Securities Exchange Act of 1934, as amended, and 18 U.S.C. §1350 | X | |||
| 101.INS | XBRL Instance Document - The instance document does not appear in the interactive data file because its XBRL tags are embedded within the inline XBRL document | ||||
| 101.SCH | Inline XBRL Taxonomy Extension Schema Document | X | |||
| 101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase Document | X | |||
| 101.LAB | Inline XBRL Taxonomy Extension Label Linkbase Document | X | |||
| 101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase Document | X | |||
| 101.DEF | Inline XBRL Taxonomy Extension Definition Linkbase Document | X | |||
| 104 | Cover Page Interactive Data File (formatted as inline XBRL with applicable taxonomy extension information contained in Exhibits 101.*) | X | |||
- Furnished herewith.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.